logo
Obesity drug prices are dropping, but getting a steady supply remains a challenge

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.
The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven.
'The medications should be available, the question is at what price and can people sustain that,' said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage.
Doctors say the situation forces them to get creative in treating patients, but there's hope that prices may fall more in the future.
The drugs are still in high demand
Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity.
Zepbound brought in $2.3 billion in U.S. sales during this year's first quarter, making it one of drugmaker Eli Lilly's best sellers.
Novo Nordisk says Wegovy has about 200,000 weekly prescriptions in the U.S., where it brought in nearly $1.9 billion in first-quarter sales.
Insurance coverage is increasing — for some
The benefits consultant Mercer says more businesses with 500 or more employees are adding coverage of the injected drugs for their workers and family members.
And Novo says 85% of its patients who have coverage in the U.S. pay $25 or less per month.
Plus some patients with diabetes can get coverage of the GLP-1 drugs Ozempic and Mounjaro from Novo and Lilly that are approved to treat that condition.
But most state and federally funded Medicaid programs don't cover the drugs for obesity and neither does Medicare, the federal program mainly for people age 65 and older.
Even the plans that cover the drugs often pay only a portion of the bill, exposing patients to hundreds of dollars in monthly costs, said Dr. Beverly Tchang.
Drugmakers offer help with these out-of-pocket costs, but that assistance can be limited.
'Coverage is not the same as access,' said Tchang, a New York-based doctor who serves as a paid advisor to both Novo and Lilly.
But coverage remains inconsistent
Bill-payers like employers are nervous about drugs that might be used by a lot of people indefinitely.
Some big employers have dropped coverage of the drugs due to the expense. Pharmacy benefit managers, or PBMs, also are starting to pick one brand over the other as they negotiate deals with the drugmakers.
One of the nation's largest PBMs, run by CVS Health, dropped Zepbound from its national formulary, or list of covered drugs, on July 1 in favor of Wegovy.
That forced Tchang to figure out another treatment plan for several patients, many of whom took Zepbound because it made them less nauseous.
Dr. Courtney Younglove's office sends prospective patients a video link showing them how to check their insurer's website for coverage of the drugs before they visit.
'Then some of them just cancel their appointment because they don't have coverage,' the Overland Park, Kansas, doctor said.
Cheaper compounded drugs are still being sold
Compounding pharmacies and other entities were allowed to make off-brand, cheaper copies of Wegovy and Zepbound when there was a shortage of the drugs. But the U.S. Food and Drug Administration determined earlier this year that the shortage had ended.
That should have ended the compounded versions, but there is an exception: Some compounding is permitted when a drug is personalized for the patient.
The health care company Hims & Hers Health offers compounded doses of semaglutide, the drug behind Wegovy, that adjust dose levels to help patients manage side effects. Hims says these plans start at $165 a month for 12 months, with customers paying in full upfront.
It's a contentious issue. Eli Lilly has sued pharmacies and telehealth companies trying to stop them from selling compounded versions of its products.
Novo recently ended a short-lived partnership with Hims to sell Wegovy because the telehealth company continued compounding. Novo says the compounded versions of its drug put patient safety at risk because ingredients are made by foreign suppliers not monitored by US regulators.
Hims says it checks all ingredients to make sure they meet U.S. quality and safety standards. It also uses a third-party lab to verify that a drug's strength is accurately labeled.
Prices have dropped
Both drugmakers are selling most of their doses for around $500 a month to people without insurance, a few hundred dollars less than some initial prices.
Even so, that expense would eat up about 14% of the average annual per person income in the U.S., which is around $43,000.
There are some factors that may suppress prices over time. Both companies are developing pill versions of their treatments. Those could hit the market in the next year or so, which might drive down prices for the older, injectable doses.
Younglove said some of her patients save as much as 15% by getting their doses shipped from a pharmacy in Canada. They used to get them from an Israeli pharmacy until the Canadians dropped their prices.
She says competition like this, plus the introduction of pill versions, will pressure U.S. prices.
'I think price wars are going to drive it down,' she said. 'I think we are in the early stages. I have hope.'
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Centene Corporation (CNC) 'Was So Brutal,' Says Jim Cramer
Centene Corporation (CNC) 'Was So Brutal,' Says Jim Cramer

Yahoo

timean hour ago

  • Yahoo

Centene Corporation (CNC) 'Was So Brutal,' Says Jim Cramer

We recently published . Centene Corporation (NYSE:CNC) is one of the stocks Jim Cramer recently discussed. Centene Corporation (NYSE:CNC) is another healthcare benefits management company. The firm's shares were decimated in July after they fell by an unbelievable 41%. The stock was obliterated after Centene Corporation (NYSE:CNC) stunned investors by pulling its fiscal year 2025 guidance. The firm explained that weaker enrollments and higher-than-expected illnesses among patients had fueled the decision. Safe to say, 'brutal' might be an understatement for the blow dealt to Centene Corporation (NYSE:CNC): 'Centene was so brutal. Brutal because the late Michael Neidorff, who was just a regular guest on Mad Money, he figured out how to provide high care, good care for HCA. But if you're not going to get paid, it's the worst possible combination. A doctor holding a clipboard in a hospital ward, discussing patient treatment plan with the nurses. Previously, Cramer discussed Centene Corporation (NYSE:CNC)'s business after the 40% crash: 'Today, some of the biggest losers in the market were a handful of managed care companies led by a company called Centene… That stock plunged over 40%. This is the worst single-day performance on record because last night after the close, the company withdrew its full-year forecast… And what's left now that the more healthy people are no longer enrolling is a less healthy population, which, of course, is bad news for the insurers. Because Centene's the largest player in the healthcare exchange space, they're getting the hardest hit, okay? Unfortunately, I think the situation's only going to get worse. In order to account for the new situation, Centene will likely have to raise its premiums, which will lead to fewer people enrolling… While we acknowledge the potential of CNC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

Trump's attorney general drops fraud case tied to COVID vaccinations
Trump's attorney general drops fraud case tied to COVID vaccinations

Yahoo

timean hour ago

  • Yahoo

Trump's attorney general drops fraud case tied to COVID vaccinations

WASHINGTON (Reuters) -U.S. Attorney General Pam Bondi on Saturday dropped a case against a Utah doctor accused of falsifying COVID-19 vaccination certificates and destroying more than $28,000 worth of government-provided COVID-19 vaccines. Bondi, in a statement posted on X, said Michael Kirk Moore Jr., of Salt Lake County, Utah did not deserve the jail time he was facing. Moore was indicted by a federal grand jury in 2023 and his trial had begun earlier this month. "Dr. Moore gave his patients a choice when the federal government refused to do so. He did not deserve the years in prison he was facing. It ends today," Bondi said. COVID-19 vaccine skeptics have been embraced by the Trump administration. The Pentagon, for example, has sought to re-enlist servicemembers who were ousted for refusing to be vaccinated during the pandemic. Health Secretary Robert F. Kennedy Jr., who for decades has sown doubt about the safety of vaccines contrary to evidence and research by scientists, wrote on X in April: "Dr. Moore deserves a medal for his courage and his commitment to healing!" According to a 2023 statement from the U.S. Attorney's Office in Utah, Moore allegedly ran the false certifications out of a plastic surgery center. His activities allegedly included administering saline shots to minors, at the request of their parents, so the children would think they were receiving COVID-19 vaccines, the statement said. Marjorie Taylor Greene, a U.S. lawmaker from Georgia and staunch Trump supporter, had championed dropping the case against Moore, who she called a hero in a statement on Saturday. "We can never again allow our government to turn tyrannical under our watch," she said in a post on X. The latest move by Bondi comes amid scrutiny of her firings of senior Justice Department officials who worked on investigations into Trump, stoking accusations of political retribution in a department whose mission is to enforce U.S. laws.

Unhealthy smoke from Canadian wildfires blankets the Upper Midwest when people want to be outside
Unhealthy smoke from Canadian wildfires blankets the Upper Midwest when people want to be outside

Washington Post

timean hour ago

  • Washington Post

Unhealthy smoke from Canadian wildfires blankets the Upper Midwest when people want to be outside

BISMARCK, N.D. — Much of the Upper Midwest on Saturday was dealing with swaths of unhealthy air due to drifting smoke from Canadian wildfires, covering the northern region of the U.S. at a time when people want to be enjoying lakes, trails and the great outdoors. Most of Minnesota and parts of Montana, North Dakota and Wisconsin were ranked 'unhealthy' for air quality on a U.S. Environmental Protection Agency map. Part of North Dakota that is home to Theodore Roosevelt National Park and other tourist attractions was ranked 'very unhealthy,' some of the worst air quality in the nation.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store